Left ventricular non-compaction (LVNC) is the third most prevalent cardiomyopathy in children and its pathogenesis has been associated with the developmental defect of the embryonic myocardium. We show that patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) generated from LVNC patients carrying a mutation in the cardiac transcription factor TBX20 recapitulate a key aspect of the pathological phenotype at the single-cell level and this was associated with perturbed transforming growth factor beta (TGF-β) signalling. LVNC iPSC-CMs have decreased proliferative capacity due to abnormal activation of TGF-β signalling. TBX20 regulates the expression of TGF-β signalling modifiers including one known to be a genetic cause of LVNC, PRDM16, and genome editing of PRDM16 caused proliferation defects in iPSC-CMs. Inhibition of TGF-β signalling and genome correction of the TBX20 mutation were sufficient to reverse the disease phenotype. Our study demonstrates that iPSC-CMs are a useful tool for the exploration of pathological mechanisms underlying poorly understood cardiomyopathies including LVNC.
Left ventricular non-compaction (LVNC) is increasingly recognized as a cause of cardiomyopathy 1, 2 , especially in children. In a recent study, LVNC accounted for 9.2% of all children with primary cardiomyopathies, and was the third most prevalent form of cardiomyopathy, after dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy 2 . LVNC is characterized by deep and extensive hypertrabeculation of the left ventricle, and causes heart failure, arrhythmias and thromboembolism.
LVNC has been theorized to result from the arrest of compaction of the developing LV myocardium, as it passes through several distinct evolutionarily conserved steps. Trabeculations in the human embryo emerge after looping of the primitive heart tube at the end of the fourth week of gestation 3 . Trabecular remodelling begins at 8 weeks with an increase in LV volume compressing the trabeculations, leading to an increase in the thickness of the compacted myocardium. Serial pathologic studies suggest that LVNC arises from impaired/arrested compaction of the myocardium, or abnormalities of vascularization, or in development of the multilayered spiral system 3, 4 . Among these steps, emergence of trabeculations and trabecular remodelling are thought to be the key steps to understanding LVNC. The trabeculation patterns are ventricle-specific, which are generally thicker and the corresponding intertrabecular spaces are larger in the LV than in the right ventricle. When this embryonic pattern persists postnatally, the morphologic appearance strongly resembles the embryonic 'spongiform' myocardium, which was the original nomenclature for this cardiomyopathy. cardiomyocytes, it is thought that the abnormal proliferation of embryonic cardiomyocytes may be associated with the pathogenesis of LVNC. However, studies have differed on whether this proliferation is increased or decreased [5] [6] [7] 9 . Furthermore, recent human studies have identified mutations in genes that are associated with regulation of cardiomyocyte proliferation 11, 12 . However, it is still unclear which phenotypes in developing cardiomyocytes are actually associated with the pathogenesis seen in humans and investigation of this disease has been challenging due to its complex genetic basis.
To overcome the problems for the investigation of human cardiac cell development with a pathological background of LVNC, we used patient-specific induced pluripotent stem cells (iPSCs). Here we demonstrated the use of human iPSC-derived cardiomyocytes (iPSC-CMs) from patients carrying the TBX20 mutation affected by LVNC as a model to define cell-specific phenotypes and elucidate potential mechanisms of this disease.
RESULTS

TBX20 mutation is a candidate genetic cause of LVNC
To identify potential genetic causes of LVNC, we recruited a family with LVNC including the proband no. 1 (A-III-4), who had undergone heart transplantation for restrictive physiology, two siblings (A-III-2 and A-III-3) with significantly deeper and more extensive trabeculation of the left ventricle (a forme fruste of LVNC referred to clinically as 'hypertrabeculation') but with normal systolic function, and the father (A-II-2) with asymptomatic DCM without LVNC (Fig. 1a-c and Supplementary Table 1 ). Genetic testing by genome-wide exome sequencing revealed a stop-gain mutation in the TBX20 gene (Y317 * ) in the proband no. 1, two siblings, and father ( Fig. 1d ). No mutations in maternally transmitted and de novo modifiers known to contribute to cardiomyopathies were detected (Supplementary Table 2 ). To investigate whether TBX20 mutations are seen in other LVNC patients, we performed genetic testing in an additional 77 LVNC patients and detected another de novo mutation (T262M) from one additional isolated LVNC patient (proband no. 2: B-II-2) ( Fig. 1a,b,d and Supplementary Table 1 ).
TBX20 is an essential cardiac transcription factor that regulates cardiomyocyte differentiation and proliferation 13, 14 . TBX20 has also been described in conjunction with congenital heart disease [15] [16] [17] and DCM 18, 19 . The TBX20 Y317 * mutation resulted in a truncated protein ( Fig. 1e ). TBX20 Y317 * and T262M mutant proteins showed disturbed synergistic activity with other cardiac transcription factors, including NKX2-5, GATA4 and TBX5 ( Supplementary Fig. 1a,b ). Furthermore, both TBX20 Y317 * and T262M mutations were found to impair the negative transcriptional regulatory function of TBX20 compared with the wild type ( Supplementary Fig. 1c ). These results suggest that LVNC-associated mutations caused disturbance of transcriptional regulation by TBX20.
LVNC iPSC-CMs possess a defect of proliferative capacity
To investigate the pathological mechanism of LVNC, we generated iPSCs using Sendai virus reprogramming from a family with an LVNC history along with three unrelated control volunteers 20, 21 ; two clones per patient were established ( Supplementary Fig. 1d -f and Supplementary Table 3 ). We classed all lines into three subgroups: unrelated control, mild DCM (A-II-2) and LVNC (A-III-2, 3, 4). iPSCs were differentiated into cardiomyocytes (iPSC-CMs) 22 , followed by glucose deprivation to enrich for iPSC-CMs ( Supplementary Fig. 2a ) 23 . Although LVNC iPSC-CMs were similar to control iPSC-CMs in terms of structural and electrophysiological phenotype as well as sarcomeric gene expression at 2-4 weeks, LVNC iPSC-CMs showed an approximately 50% reduction of the expression of TBX20 downstream target genes compared with control iPSC-CMs ( Fig. 1f and Supplementary Fig. 2b-j and Supplementary Table 4 ). Furthermore, the differentiation efficiency was also halved in LVNC iPSC lines compared with the control prior to glucose deprivation ( Fig. 1g ). On the other hand, mild DCM iPSC-CMs showed intermediate defects in TBX20 target gene expression and differentiation efficiency between LVNC and control iPSC-CMs. Despite comparable expression of mesodermal markers including MESP1 and brachyury (T) across all lines during cardiac differentiation ( Supplementary Fig. 2k ), LVNC iPSCs had significantly lower expression of cardiac transcription factors compared with control cell lines especially between day 6 and 9 ( Fig. 1h and Supplementary Fig. 3a ). These results suggest an impaired induction of cardiac lineage from mesodermal progenitors in LVNC iPSCs.
Since past human and mouse studies have shown possible association between cell-cycle defects in developing cardiomyocytes and pathogenesis of LVNC [5] [6] [7] 12, 24 , we next assessed the proliferative potential in iPSC-CMs. We found that iPSC-CMs were responsive to growth factors and had increased numbers within 3 weeks after induction of differentiation although their growth was temporary ( Supplementary Fig. 3b ). To assess the proliferation potential in developing iPSC-CMs, the distribution of S-phase cardiomyocytes was validated by EdU incorporation with or without stimulation of serum or growth factors. LVNC iPSC-CMs showed reduced baseline proliferative capacity by ∼50% without any stimulation as well as in the presence of serum and growth factors compared with control cells at an earlier time point (2 weeks), whereas mild DCM iPSC-CMs showed a milder reduction of ∼30% compared with control ( Fig. 1i,j) . On the other hand, undifferentiated iPSCs showed no significant difference in their growth speed ( Supplementary Fig. 3c ), suggesting that the proliferation defect may be characteristic in differentiated cardiac cells.
Abnormal activation of TGF-β signalling is associated with proliferation defect in LVNC iPSC-CMs
To clarify potential signalling pathways associated with the proliferation defect in LVNC iPSC-CMs, we next performed RNA-sequencing using control, mild DCM, and LVNC iPSC-CMs at 2 weeks. Upstream regulator analysis predicted that activation of TGF-β signalling may be potentially responsible for this differential gene expression between control and LVNC iPSC-CMs ( Fig. 2a and Supplementary Fig. 4a and Supplementary Table 5 ). Most of the TGF-β signalling pathway, especially TGF-β1-associated genes, were upregulated in LVNC and mild DCM iPSC-CMs compared with control iPSC-CMs ( Fig. 2b and Supplementary Fig. 4b,c ). Previous studies have shown that aberrant TGF-β signalling causes incomplete compaction of myocardium in mice 6, 9 , and that TGF-β signalling inhibits proliferation of embryonic cardiomyocytes 25, 26 via upregulation of cyclin-dependent kinase inhibitors (CKIs) including CDKN1A [27] [28] [29] . Consistent with these studies, LVNC iPSC-CMs showed significant upregulation of TGF-β signalling-related genes and 1.7-fold higher phosphorylation of SMAD2/3 ( Fig. 2c and Mild DCM  III-3 III-3  III-2  III-1  II 2w PBS 2w TGFB1 1 ng ml -1 2w TGFB1 5 ng ml -1 2w TGFB1 25 ng ml -1 2w TGFB2 5 ng ml -1 2w TGFB3 5 ng ml -1 4w PBS 4w TGFB1 1 ng ml -1 4w TGFB1 5 ng ml -1 4w TGFB1 25 ng ml -1 4w TGFB2 5 ng ml -1 4w TGFB3 5 ng ml -1 * * * * * * * * * * * * * * Supplementary Table 12 . Unprocessed original scans of blots are shown in Supplementary Fig. 8 . Supplementary Fig. 4d,e ), whereas mild DCM iPSC-CMs had less phosphorylation (1.2-fold versus control). LVNC iPSC-CMs also showed a 1.8-fold increased CDKN1A expression compared with control iPSC-CMs ( Fig. 2d and Supplementary Fig. 4f ,g), suggesting
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that activation of the TGF-β1-CDKN1A regulatory axis may be responsible for the early cell-cycle exit seen in LVNC iPSC-CMs. Histological analysis of the proband's explanted LV myocardium revealed higher phosphorylation of SMAD2 in comparison with control LV tissue, providing further evidence of activated TGF-β signalling as a pathogenesis of LVNC ( Fig. 2e ). Interestingly, LVNC iPSC-CMs showed significantly higher expression of TGF-β signalling pathway-associated genes compared with mild DCM iPSC-CMs that were associated with milder phenotypic severity ( Supplementary Fig. 4b-g ). To understand the difference in disease severity between the father (mild DCM phenotype) and his children (LVNC phenotype), despite carrying the same TBX20 mutation, we next assessed expression of the mutant TBX20 allele by RNA-sequencing and digital droplet PCR. We found that the ratio of mutant allele against wild-type allele expression was higher in LVNC iPSC-CMs than in mild DCM iPSC-CMs ( Fig. 2f ), suggesting a dosage effect of the TBX20 mutant allele on the ectopic activation level of the TGF-β signalling pathway in patient-specific iPSC-CMs and perhaps explaining the differences in phenotypic severity among affected family members. To confirm that stimulation with TGF-β isoforms could affect the proliferation potential in iPSC-CMs, we treated control iPSC-CMs with TGF-β isoforms with or without serum or growth factors. We found that, like LVNC iPSC-CMs, TGF-β-treated control iPSC-CMs showed a significant decrease of proliferative response to serum, IGF-1, and IGF-2 stimulation at 2 weeks compared with TGF-β-untreated control iPSC-CMs (Fig. 2g ). These results suggest that activation of TGF-β signalling has a negative effect on the proliferative potential of developing cardiomyocytes.
Ectopic activation of TGF-β signalling causes a cardiomyocyte proliferation defect in vivo
To assess how abnormal TGF-β1 signalling affects myocardial development in vivo, we next generated cardiac-specific TGF-β1overexpressing transgenic mice (β1 glo /αMHC-Cre; Supplementary  Fig. 5 ). These double-transgenic mice exhibit embryonic lethality by embryonic day (E) 11.5 due to decreased proliferation in developing cardiomyocytes ( Fig. 3a-d and Supplementary Fig. 5c and d and Supplementary Table 6 ), providing further proof implicating aberrant TGF-β signalling in the embryonic heart with developmental arrest of the compact layer.
Next, to assess the later stages of compact layer development, we crossed β1 glo transgenic mice with NK-TGCK transgenic mice that express GFP-Cre fusion protein under the control of the Nkx2-5 cardiac-specific enhancer/promoter and Tet-Off system to negatively regulate GFP-Cre expression following doxycycline (DOX) exposure ( Supplementary Fig. 5e ). The αMHC-Cre transgene labelled >90% of cardiomyocytes at E12.5 and the NK-TGCK transgene activated Cre in ∼40% of cardiomyocytes without DOX and ∼25% of cardiomyocytes with DOX treatment and showed significantly lesser TGFB1 mRNA expression compared with αMHC-Cre/β1 glo double-transgenic mouse embryos at E10.5 ( Supplementary  Fig. 5f-h) . The double-transgenic embryos carrying both NK-TGCK and β1 glo (β1 glo /NK-TGCK) without DOX treatment showed a significant increase of TGF-β downstream target genes whereas the double-transgenic embryos with DOX treatment showed only a mild increase of these genes at E10.5 ( Supplementary Fig. 5i ). The β1 glo /NK-TGCK double-transgenic embryos showed embryonic lethality around E12.5 to E13.5. In contrast, when mice were treated with DOX, the embryos could survive normally at E12.5 ( Fig. 3e and Supplementary Table 7 ). Histological analysis showed a significantly thinner compact layer and reduced Ki67 or phospho-histone H3 (PHH3)-positive cardiomyocytes in the compact layer in β1 glo /NK-TGCK double-transgenic embryos without DOX compared with wildtype littermates, although the trabecular layer was well developed in these double-transgenic embryos (Fig. 3f-h and Supplementary  Fig. 5j,k) . Half of DOX-treated β1 glo /NK-TGCK double-transgenic embryos showed reduced thickness of the LV compact layer, and the proportion of Ki67 + or PHH3 + cardiomyocytes in the compact layer in β1 glo /NK-TGCK embryos was mildly decreased compared with wild-type littermates (Fig. 3f,i,j and Supplementary Fig. 5j,k) .
To assess the fate of TGF-β1-activated CMs in DOX-treated transgenic mice, we next generated triple-transgenic embryos carrying NK-TGCK/β1 glo transgenes with a Cre-dependent tdTomato overexpression system (Ai14) 30 . We found that the proportion of TGF-β1-activated CMs in LV was significantly decreased in tripletransgenic embryos and neonates during development compared with control (NK-TGCK/Ai14) mice, suggesting reduced proliferation by TGF-β-expressing CMs (Fig. 4a,b ). Furthermore, the hearts of tripletransgenic neonates at postnatal day 3 showed a thicker trabecular layer and a thinner compact layer resulting in a significantly higher non-compaction/compaction (NC/C) ratio in LV myocardium compared with control neonates (Fig. 4c-e ). Taken together, these results support the role of abnormal activation of TGF-β signalling to cause developmental arrest of cardiomyocytes in a temporal and dose-dependent manner in vivo.
Functional disturbance of TBX20 causes abnormal activation of TGF-β signalling
Next, to assess whether the defective TBX20 transcriptional cascade causes abnormal activation of TGF-β signalling, we analysed the gene expression profile of the Tbx20 knockout mouse 31 . Interestingly, messenger RNA expression analysis of Tbx20 knockout mouse heart revealed a similar gene expression profile to that of LVNC iPSC-CMs, including upregulation of TGF-β signalling ( Fig. 5a and Supplementary Table 8 ) 31 . Furthermore, ChIP-sequencing data of Tbx20 31 showed conserved TBX20-binding sites in the genes that are associated with TGF-β signalling regulation and modification between human and mouse ( Fig. 5b and Supplementary Table 9 ). This gene expression profile was significantly disturbed in LVNC iPSC-CMs compared with control iPSC-CMs, as well as in the Tbx20 knockout mouse heart compared with the wild type ( Fig. 5c,d) . We further employed short hairpin RNA (shRNA) against TBX20 in the H7 human embryonic stem cell (ESC) line (TBX20KD-H7) (Fig. 6a,b) , and found that TBX20KD-H7-CMs showed less proliferative capacity and increased expression of TGF-β-related genes compared with scramble control lines ( Fig. 6c-g) . These results confirm that the dysfunction of TBX20 is associated with the pathological proliferation phenotype of LVNC iPSC-CMs through disturbance of the TGF-β signalling.
TBX20-PRDM16 axis regulates TGF-β signalling and contributes to cardiomyocyte proliferation
To better understand the regulatory mechanism of TGF-β signalling by TBX20, we next studied TGF-β modifiers with conserved TBX20-binding sites 31 Table 9 ), and selected the PRDM16 gene as one of the potential Supplementary  Table 12. downstream targets of TBX20. PRDM16, a repressor of TGF-β signalling and a known genetic cause of LVNC and DCM, was significantly downregulated in all LVNC iPSC-CMs, TBX20KD-H7-CMs and the Tbx20 knockout mouse heart (Figs 5d and 6h,i) . A previous genetic study of human LVNC with the PRDM16 mutation also revealed that truncation in exon 9 of PRDM16 is associated with the LVNC phenotype 12 . To confirm whether LVNC iPSC-CMs with the PRDM16 mutation showed abnormal activation of TGF-β signalling and a proliferation defect, as seen in LVNC iPSC-CMs with the TBX20 mutation, we next generated a genome-edited iPSC line carrying the frameshift mutation in exon 9 of the PRDM16 gene (PRDM16fs) and induced cardiac differentiation (Fig. 6j) . Importantly, PRDM16fs iPSC-CMs showed significantly decreased proliferative response when exposed to growth factors and upregulation of TGF-β downstream Supplementary Table 12. target genes (Fig. 6k,l) . Furthermore, the explanted heart tissue of proband no. 1 showed a significant decrease of PRDM16 expression compared with control donor heart tissue ( Fig. 6m ), suggesting that the TBX20-PRDM16-TGF-β axis as one of the mechanisms causing LVNC.
between human and mouse (Supplementary
Modification of TGF-β signalling or genetic correction of the TBX20 mutation exacerbate the proliferation defect in LVNC iPSC-CMs
Finally, we evaluated whether modification of aberrant TGF-β signalling could rescue the proliferation defect in LVNC iPSC-CMs.
Inhibition of TGF-β signalling with TGF-β receptor-1 inhibitors or overexpression of a dominant-negative form of TGF-β receptor-2 increased S-phase cells in both LVNC iPSC-CMs and TBX20KD-H7-CMs compared with untreated cells (Fig. 7a-c and Supplementary  Fig. 6 ). Likewise, knockdown of the downstream effector CDKN1A also improved the distribution of S-phase LVNC iPSC-CMs ( Fig. 7d-f ). To validate the effects of the TBX20 Y317 * mutation on the phenotype of LVNC iPSC-CMs, we generated TBX20 Y317 * mutation-corrected (LVNC-corrected) iPSCs from the proband's iPSCs ( Supplementary Fig. 7a-e ). LVNC-corrected iPSC-CMs showed increased cardiac differentiation efficiency, expression of a cardiac transcription factors, and restored proliferative capacity compared with non-corrected LVNC iPSC-CMs along with decreased TGF-β signalling activity ( Fig. 7g-k) . These results suggest that the TBX20 mutation contributes to the pathological phenotype of LVNC iPSC-CMs via disturbance of TGF-β signalling, which is associated with developmental defects of the compact layer during embryogenesis ( Supplementary Fig. 7f ).
DISCUSSION
Previously, both accelerative 9, 11 and decelerative proliferation [5] [6] [7] 12 in embryonic cardiomyocytes have been reported in animal models. In our transgenic mouse model, high overexpression of TGFB1 in the developing myocardium led to a severe developmental arrest in the compact layer and the severity of this non-compaction phenotype was directly correlated with the levels of TGFB1 overexpression. These 
Scrambled (N = 9) TBX20KD (N = 9)
Relative mRNA expression normalized by GAPDH * observations suggest that at the early developmental stage of LV compact layer remodelling, proper activation of TGF-β signalling in the embryonic heart is required to ensure normal ventricular development.
Human iPSC-CMs have been used to model familial DCM 23, 32, 33 , familial hypertrophic cardiomyopathy 34, 35 , long QT syndrome 36, 37 , and chemotherapy-induced cardiomyopathy 38 , among others 39 . In this study, we demonstrate that iPSC-CM technology is useful not only for delineating the detailed molecular pathogenesis of congenital developmental defects, but also to clarify genetic causes in such diseases. We successfully found an association between functional disturbance of TBX20 and ectopic activation of TGF-β signalling in Supplementary  Table 12 . Unprocessed original scans of blots are shown in Supplementary  Fig. 8 .
patient-specific iPSC-CMs as well as perturbed regulation of putative downstream targets of TBX20. We showed that PRDM16 is a possible downstream target gene of TBX20. PRDM16 is a known cause of LVNC in humans and morpholino knockdown of PRDM16 causes a proliferation defect in the developing zebrafish heart 12 . PRDM16 is a repressor of TGF-β signalling [40] [41] [42] via binding of SMAD2/3, and our results revealed ectopic activation of TGF-β signalling in LVNC iPSC-CMs consistent with these previous studies. Although the comprehensive RNA expression data and ChIP-sequencing data showed that TBX20 has a large number of potential downstream target genes associated with TGF-β signalling regulation, our data suggest that the TBX20/PRDM16/TGF-β signalling pathway may be one of the key regulatory cascades for proper development of the compact/trabecular layer. It is known that patients with LVNC generally show a wide spectrum of clinical manifestations. Some are asymptomatic, and the age at presentation can vary considerably, from as early as the newborn period to as late as older adulthood 43, 44 . This may be explained by varying expression levels of mutant allele-specific mRNA expression between mild DCM and LVNC as shown here. TBX20 is known to interact with other cardiac transcription factors including NKX2-5, GATA4 and TBX5 that are essential for embryonic cardiomyocyte proliferation and ventricular development. As shown here, the disturbance of the interaction between TBX20 and these cardiac transcription factors may negatively impact the expansion of embryonic cardiomyocytes and impair the formation of the multilayered compact myocardium ( Supplementary Fig. 7f ). The differences of allele-specific TBX20 expression and the background expression of these cardiac transcription factors that may also be affected by heterogeneous factors could then impact the various cardiac phenotypes in patients with TBX20 mutations.
In conclusion, iPSC-CMs recapitulate the proliferative defects associated with LVNC 5-7,12 at the single-cell level. Importantly, this study presents the supporting evidence of a proliferation defect, a consequence of abnormal activation of TGF-β signalling, as a pathological feature of human LVNC. Whether this defect is common to all cases of LVNC or just a genetic subset remains to be determined. Our data suggest that iPSC-CMs may be useful in therapeutic screening to identify potential interventions for this cardiomyopathy in the future.
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